"The phase 2, open-label, multicenter study will r

"The phase 2, open-label, multicenter study will randomly assign approximately 60 patients with CCR5-positive MSS mCRC to receive either 350 mg or 700 mg of leronlimab. Patients will be divided into 2 cohorts, with an initial safety lead-in group receiving the 350 mg dose before advancing to the higher dose group. Leronlimab will be administered weekly, while TAS-102 and bevacizumab will be given on a 3- or 4-week schedule within a 4-week cycle."

https://www.targetedonc.com/view/fda-clears-p...stable-crc

That part about before advancing to the 700mg group will be up the DSMB and FDA, but my guess is it'll go to 700mg for all, and enrollment will accelerate.